# Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

Study · id `cardio:ct-nct02086045` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02086045](<https://clinicaltrials.gov/study/NCT02086045>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02086045

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

## Technical summary

Registry record NCT02086045. Allocation not applicable; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 126 participants (enrolled count; ClinicalTrials.gov record NCT02086045, source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT02086045, source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)
- Primary completion: 2013-06 (actual) (ClinicalTrials.gov record NCT02086045, source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)
- Completion: 2017-05-15 (actual) (ClinicalTrials.gov record NCT02086045, source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)
- Countries: Belgium; Brazil; Denmark; Germany; New Zealand; Poland (ClinicalTrials.gov record NCT02086045, source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02086045-2023-09-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
- Condition: Coronary Artery Disease
- Intervention (Device): DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
- Lead sponsor: Elixir Medical Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Elixir Medical Corporation (`cardio:org-elixir-medical-corporation`)

## Provenance

Content hash: 53c804c2f8157e34054a2f1817a5757f6694bc3abadb571472d81dafc2221b10
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
